NIH Conflict-Of-Interest Final Rule Sets Clock For Pharma Stock Divestiture
This article was originally published in The Pink Sheet Daily
Executive Summary
Final rule on ethical conduct allows employee compensation from trade associations, though consulting agreements with pharma/biotech companies are still prohibited.
You may also be interested in...
NIH New Conflict Of Interest Regulations Take Effect Immediately Upon Publication
Scientists will have 30 days to sever consulting ties with pharmaceutical and biotech companies to comply with new conflict of interest regulations. The new rules are part of an HHS interim final rule that also amends existing regulations for other HHS agencies.
Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled
The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.
GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG
HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.